Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
Melissa L. Sokolosky(East Carolina University), James A. McCubrey(East Carolina University), Stephen L. Abrams(East Carolina University), Massimo Libra(University of Catania), Richard A. Franklin(Kamineni Institute of Dental Sciences), Kristin M. Stadelman(East Carolina University), Alberto M. Martelli(University of Bologna), Л. Б. Дробот(Palladin Institute of Biochemistry), Ferdinando Nicoletti(University of Catania), William H. Chappell(University of North Carolina at Chapel Hill), Linda S. Steelman(East Carolina University), Franca Stivala(University of Catania)
Cited by 82
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508